Latest Cashflow News

PhosCo Ltd has delivered maiden Mineral Resource Estimates for the KM and SAB phosphate deposits at its Gasaat Project in Tunisia, adding 20.2 Mt at 20.5% P₂O₅ and lifting the total resource to 166.6 Mt. The shallow, low-strip deposits promise improved early production and underpin an updated scoping study due in Q3 2026.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

Redcastle Resources has secured a 60% earn-in to the Kilkenny Belt Package, adding 64km² of tenements adjacent to its existing Eastern Goldfields holdings and reinforcing its dual strategy of near-term development and regional exploration.

Manuka Resources has drawn down a US$26 million tranche of a US$30 million debt facility, exited care and maintenance at Wonawinta, and signed a major mining contract as it targets production restart in late Q2 2026.

Sunshine Metals is set to transform its gold production profile with the $18 million acquisition of the Mt Moss processing facility and a $22 million capital raise to fund expansion and exploration.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

Pointerra Limited delivered a 214% jump in Q3 FY26 customer receipts to A$2.2 million, driven by milestone invoicing and new Tier 1 utility contracts, edging closer to operating cashflow breakeven.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

TG Metals reports exceptional metallurgical results from heap leach testwork on Laterite gold at Van Uden, unlocking a potential low-cost, near-term cashflow opportunity from over one million tonnes of surface material.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Dubber Corporation reported a historic positive underlying operating cashflow run-rate in Q3 FY26, driven by a USD 3.06 million initial payment from a Tier 1 North American communications service provider and ongoing cost reductions. Recurring revenue dipped 6% quarter-on-quarter due to portfolio optimisation and foreign exchange impacts.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.